What was recalled
This page synthesizes the microbial single-cell protein (SCP) framework around commercial pet food alternative protein development. SCP refers to protein produced from single-celled microorganisms grown through industrial fermentation, distinct from precision fermentation (which produces specific recombinant animal proteins, covered on our precision-fermented animal protein page) by using the whole microbial biomass as the protein source rather than purifying specific protein products. The category has substantial industrial heritage in livestock feed and aquaculture feed applications dating to the 1960s-1970s research era.
The industrial SCP heritage includes several notable commercial developments. BP Pruteen process (1970s-1980s) produced bacterial SCP from Methylophilus methylotrophus grown on methanol substrate for animal feed applications; the process was commercialized at industrial scale in the UK but discontinued in the 1980s due to soybean meal cost competitiveness. Calysta FeedKind (2010s-2020s) produces SCP from Methylococcus capsulatus grown on natural gas (methane) substrate for fish feed and aquaculture feed applications, with commercial production at Cargill-Calysta joint facility and growing market presence. KnipBio (2010s-2020s) produces SCP from Methylobacterium for aquaculture feed and pet food applications with FDA-CVM regulatory engagement. Calysta and KnipBio represent the dominant bacterial SCP commercial pet food development as of 2024.
The yeast-derived SCP heritage is even longer-established. Torula yeast (Candida utilis) was commercialized starting in the early 20th century as animal feed protein and human food protein source, with industrial production continuing in multiple regions globally. Saccharomyces cerevisiae brewer's yeast and baker's yeast derivatives have AAFCO definitions for animal feed applications including pet food. Yarrowia lipolytica is a newer commercial yeast SCP with lipid-rich biomass profile, used in aquaculture feed and emerging pet food applications. Aspergillus oryzae Koji fermentation (used by Wild Earth for vegan dog food) operates at the SCP / mycoprotein interface, producing fungal biomass with complete amino acid profile and substantial protein content. Wild Earth received FDA-CVM no-questions-letter for its Koji-derived protein and operates commercial vegan dog food product line with established US pet food market presence.
Why it was recalled
The structural concerns have three layers. Layer one — AAFCO definition framework is fragmented across SCP categories: some SCP variants have established AAFCO definitions (yeast derivatives including Saccharomyces cerevisiae brewer's yeast, dried torula yeast, others) supporting commercial pet food applications. Other SCP variants (bacterial SCP from Methylophilus or Methylococcus, novel yeast SCP from Yarrowia lipolytica, filamentous fungi SCP) lack specific AAFCO definitions and operate through alternative regulatory pathways (FDA-CVM no-questions-letters, FDA GRAS self-affirmation, state-level cross-reference from established animal feed applications). The fragmented framework produces variable regulatory rigor across SCP variants in commercial pet food, with consumer-disclosure transparency around SCP source organism and regulatory pathway typically absent.
Layer two — novel substrate considerations for bacterial SCP: bacterial SCP variants grown on novel substrates (natural gas methane for Calysta FeedKind, methanol for BP Pruteen historically) involve substrate considerations distinct from traditional SCP grown on agricultural substrates. Regulatory review addresses substrate-related safety considerations (residual substrate concerns, host bacterial genetics, fermentation byproducts), with the framework evolving as commercial scale grows. The novel-substrate framework places these bacterial SCP variants at higher regulatory complexity than yeast SCP variants with longer commercial heritage.
Layer three — long-term companion animal feeding evidence varies across SCP variants: yeast SCP variants (brewer's yeast, torula yeast) have substantial long-term companion animal feeding evidence from decades of commercial pet food applications. Bacterial SCP variants (Methylococcus FeedKind, Methylobacterium KnipBio) have shorter feeding evidence base in companion animals, with most evidence from aquaculture and livestock feed applications. Filamentous fungi SCP (Aspergillus oryzae Koji for Wild Earth, novel Aspergillus variants emerging) has growing commercial pet food evidence but still less established than traditional yeast SCP. The framework produces a spectrum of evidence quality across SCP variants that consumer-facing marketing rarely captures.
Health risks for your pet
Microbial single-cell protein produced through established industrial fermentation operations meets food safety requirements equivalent to other regulated pet food ingredients. The nutritional adequacy varies across SCP variants: yeast-derived SCP typically provides high-quality protein with complete amino acid profile and substantial B-vitamin content; bacterial SCP provides high-protein-density biomass with favorable amino acid profile; filamentous fungi SCP provides complete amino acid profile with chitin-containing cell walls offering potential prebiotic effect. Theoretical health-impact concerns vary by SCP variant: (i) nucleic acid content — SCP biomass typically contains 6-12% nucleic acids on dry-matter basis, higher than conventional protein sources; high nucleic acid intake can affect uric acid metabolism in some species; pet food formulations typically use moderate SCP inclusion rates to manage this; (ii) cell wall composition — yeast cell walls contain beta-glucan and mannan-oligosaccharides with potential immunomodulatory effect; fungal cell walls contain chitin with potential prebiotic effect; bacterial cell walls have variable composition depending on Gram-positive vs Gram-negative classification; (iii) residual substrate or fermentation byproducts — novel-substrate SCP variants require downstream processing controls to minimize residual substrate (methanol, methane oxidation byproducts); (iv) palatability variation — some SCP variants have distinct flavor profiles requiring formulation considerations for pet acceptance.
The more substantive consideration is variant-specific regulatory and evidence quality: SCP variants vary substantially in AAFCO definition status, FDA-CVM regulatory engagement, and long-term companion animal feeding evidence base. Established yeast SCP variants (brewer's yeast, torula yeast) have strong regulatory and evidence framework; emerging bacterial and filamentous fungi SCP variants have developing framework. Brand-level transparency around SCP source organism, regulatory pathway, and feeding evidence would help consumers interpret the category meaningfully, but commercial pet food consumer-facing marketing typically does not capture this granularity.
What to do if you bought affected product
Pet owners can navigate microbial single-cell protein pet food meaningfully through several practical approaches: (1) recognize that SCP is a heterogeneous category spanning bacterial SCP, yeast SCP, and filamentous fungi SCP with substantively different regulatory and evidence profiles; (2) established yeast SCP (brewer's yeast, torula yeast) has decades of commercial pet food heritage with AAFCO definitions and strong long-term feeding evidence — these ingredients in pet food are well-characterized; (3) emerging bacterial SCP (Calysta FeedKind, KnipBio) and filamentous fungi SCP (Wild Earth Koji) are innovation-tier ingredients with developing regulatory framework and growing but still-emerging companion animal feeding evidence; (4) verify regulatory pathway disclosure from brand customer service for novel SCP variants — ask which regulatory pathway applies (AAFCO definition for established yeast SCP, FDA-CVM no-questions-letter for emerging variants, FDA GRAS self-affirmation, FDA food additive petition); (5) recognize the sustainability advantages — SCP generally offers favorable sustainability profile (substantially lower land footprint than livestock agriculture, ability to use diverse substrates including agricultural side-streams and natural gas, fast production cycle); (6) introduce novel SCP-containing pet food gradually over a 1-2 week transition period; (7) discuss SCP-containing pet food options with your veterinarian for pets with chronic conditions, kidney disease (high nucleic acid content consideration), or specific dietary needs; (8) treat SCP as one of several alternative protein options alongside insect protein, precision-fermented animal protein, and cultured meat — the categories have complementary characteristics and the choice depends on formulation, regulatory, and consumer-preference considerations.
How this affects KibbleIQ’s grade
The KibbleIQ rubric v15 includes established yeast SCP variants (brewer's yeast, torula yeast) in the ingredients database where they appear in pet food formulations per our published methodology. Novel SCP variants (bacterial SCP, filamentous fungi SCP) are not yet broadly included pending broader US commercial pet food adoption and AAFCO definition framework maturation. Future rubric extension under consideration: as novel SCP variants reach broader commercial pet food adoption with AAFCO definitions or established FDA-CVM regulatory pathway, rubric integration would address nutritional adequacy (complete amino acid profile, B-vitamin content), sustainability favorability (substantially better than conventional animal sourcing), and developing long-term feeding evidence. The broader alternative protein and emerging-category framework is covered across our mycoprotein, yeast biomass protein, precision-fermented animal protein, black soldier fly larvae, and tranche-14 alternative protein controversy pages. For now, our recommendation: trust established yeast SCP in pet food, treat emerging bacterial and filamentous fungi SCP as innovation-tier ingredients.